Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Assets: 2017-2025

Historic Other Non-Current Assets for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $2.1 million.

  • Puma Biotechnology's Other Non-Current Assets fell 5.79% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 5.79%. This contributed to the annual value of $2.1 million for FY2024, which is 23.19% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Other Non-Current Assets is $2.1 million, which was down 0.00% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Other Non-Current Assets peaked at $12.2 million during Q1 2021, and registered a low of $2.1 million during Q4 2024.
  • Its 3-year average for Other Non-Current Assets is $2.4 million, with a median of $2.3 million in 2024.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 78.69% in 2022, then climbed by 11.85% in 2023.
  • Puma Biotechnology's Other Non-Current Assets (Quarterly) stood at $12.2 million in 2021, then plummeted by 78.69% to $2.6 million in 2022, then climbed by 5.15% to $2.7 million in 2023, then dropped by 23.19% to $2.1 million in 2024, then declined by 5.79% to $2.1 million in 2025.
  • Its Other Non-Current Assets stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.1 million for Q1 2025.